T1	p 42 48	humans
T2	p 335 361	healthy young subjects was
T3	p 431 466	Five groups of 8 subjects each were
T4	p 495 496	)
T5	p 500 511	torcetrapib
T6	p 518 519	)
T7	i 188 222	cholesteryl ester transfer protein
T8	i 232 253	inhibitor torcetrapib
T9	i 481 519	placebo ( n=2 ) or torcetrapib ( n=6 )
T10	i 542 554	120 mg daily
T11	i 559 565	120 mg
T12	i 592 603	Torcetrapib
T13	o 278 331	high-density lipoprotein cholesterol ( HDL-C ) levels
T14	o 613 622	tolerated
T15	o 690 727	of plasma drug levels with inhibition
T16	o 963 976	elevations of
T17	o 1001 1025	Total plasma cholesterol
T18	o 1129 1164	low-density lipoprotein cholesterol
T19	o 1187 1209	Apolipoprotein A-I and
T20	o 1345 1361	and triglyceride
T21	o 1386 1401	plasma fraction